Public Employees Retirement Association of Colorado grew its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 17,519 shares of the company’s stock after purchasing an additional 556 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in IDEXX Laboratories were worth $2,740,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. Advisors Capital Management LLC acquired a new stake in IDEXX Laboratories during the third quarter worth about $262,000. Wells Fargo & Company MN raised its stake in IDEXX Laboratories by 7.8% during the third quarter. Wells Fargo & Company MN now owns 338,968 shares of the company’s stock worth $52,706,000 after acquiring an additional 24,510 shares during the period. Cabot Wealth Management Inc. acquired a new stake in IDEXX Laboratories during the third quarter worth about $1,359,000. Macquarie Group Ltd. raised its stake in IDEXX Laboratories by 7.0% during the third quarter. Macquarie Group Ltd. now owns 38,000 shares of the company’s stock worth $5,909,000 after acquiring an additional 2,500 shares during the period. Finally, Atlantic Trust Group LLC acquired a new stake in IDEXX Laboratories during the third quarter worth about $65,381,000. Institutional investors and hedge funds own 86.50% of the company’s stock.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $175.39 on Wednesday. IDEXX Laboratories, Inc. has a 1 year low of $140.63 and a 1 year high of $198.73. The company has a quick ratio of 0.80, a current ratio of 0.97 and a debt-to-equity ratio of -11.26. The company has a market cap of $15,268.51, a PE ratio of 59.66, a price-to-earnings-growth ratio of 2.15 and a beta of 0.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The firm had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same quarter in the prior year, the firm earned $0.58 EPS. IDEXX Laboratories’s quarterly revenue was up 14.2% on a year-over-year basis. sell-side analysts forecast that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current year.

Several equities research analysts recently weighed in on the stock. BidaskClub lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 9th. Canaccord Genuity restated a “buy” rating and issued a $210.00 target price on shares of IDEXX Laboratories in a research report on Monday, January 29th. Piper Jaffray Companies upped their target price on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 target price for the company in a research report on Monday, February 5th. Finally, Bank of America upped their target price on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. IDEXX Laboratories currently has a consensus rating of “Buy” and a consensus price target of $194.00.

In other news, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $153.61, for a total value of $2,764,980.00. Following the completion of the transaction, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,529,058.53. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Brian P. Mckeon sold 6,602 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $181.36, for a total transaction of $1,197,338.72. Following the completion of the transaction, the vice president now owns 47,040 shares of the company’s stock, valued at $8,531,174.40. The disclosure for this sale can be found here. In the last 90 days, insiders sold 104,762 shares of company stock valued at $17,967,464. 2.77% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “IDEXX Laboratories, Inc. (IDXX) Stake Raised by Public Employees Retirement Association of Colorado” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://theolympiareport.com/2018/02/14/idexx-laboratories-inc-idxx-stake-raised-by-public-employees-retirement-association-of-colorado.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.